Evidence map›Paper›PMID 38672459›Full record

ArticleBiomolecules2024

Transient Receptor Potential Canonical 5 (TRPC5): Regulation of Heart Rate and Protection against Pathological Cardiac Hypertrophy.

Pratish Thakore, James E Clark, Aisah A Aubdool, Dibesh Thapa, Anna Starr, Paul A Fraser, Keith Farrell-Dillon, Elizabeth S Fernandes, Ian McFadzean, Susan D Brain

Open access · goldAbstract read
In one paragraph

Article in Biomolecules, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Pratish ThakoreBHF Cardiovascular Centre of Research Excellence, School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, London SE1 9NH, UK.
James E ClarkBHF Cardiovascular Centre of Research Excellence, School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, London SE1 9NH, UK.ORCID 0000-0001-7574-2162
Aisah A AubdoolBHF Cardiovascular Centre of Research Excellence, School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, London SE1 9NH, UK.
Dibesh ThapaBHF Cardiovascular Centre of Research Excellence, School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, London SE1 9NH, UK.ORCID 0000-0002-7435-5483
Anna StarrBHF Cardiovascular Centre of Research Excellence, School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, London SE1 9NH, UK.
Paul A FraserBHF Cardiovascular Centre of Research Excellence, School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, London SE1 9NH, UK.
Keith Farrell-DillonBHF Cardiovascular Centre of Research Excellence, School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, London SE1 9NH, UK.
Elizabeth S FernandesPrograma de Pós-Graduação, em Biotecnologia Aplicada à Saúde da Criança e do Adolescente, Instituto de Pesquisa Pelé Pequeno Príncipe, Curitiba 80230-020, PR, Brazil.ORCID 0000-0002-0567-2514
Ian McFadzeanSchool of Cancer and Pharmaceutical Sciences, King's College London, London SE1 9NH, UK.
Susan D BrainBHF Cardiovascular Centre of Research Excellence, School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, London SE1 9NH, UK.ORCID 0000-0002-9684-8342
King's College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TRPC5 is a non-selective cation channel that is expressed in cardiomyocytes, but there is a lack of knowledge of its (patho)physiological role in vivo. Here, we examine the role of TRPC5 on cardiac function under basal conditions and during cardiac hypertrophy. Cardiovascular parameters were assessed in wild-type (WT) and global TRPC5 knockout (KO) mice. Despite no difference in blood pressure or activity, heart rate was significantly reduced in TRPC5 KO mice. Echocardiography imaging revealed an increase in stroke volume, but cardiac contractility was unaffected. The reduced heart rate persisted in isolated TRPC5 KO hearts, suggesting changes in basal cardiac pacing. Heart rate was further investigated by evaluating the reflex change following drug-induced pressure changes. The reflex bradycardic response following phenylephrine was greater in TRPC5 KO mice but the tachycardic response to SNP was unchanged, indicating an enhancement in the parasympathetic control of the heart rate. Moreover, the reduction in heart rate to carbachol was greater in isolated TRPC5 KO hearts. To evaluate the role of TRPC5 in cardiac pathology, mice were subjected to abdominal aortic banding (AAB). An exaggerated cardiac hypertrophy response to AAB was observed in TRPC5 KO mice, with an increased expression of hypertrophy markers, fibrosis, reactive oxygen species, and angiogenesis. This study provides novel evidence for a direct effect of TRPC5 on cardiac function. We propose that (1) TRPC5 is required for maintaining heart rate by regulating basal cardiac pacing and in response to pressure lowering, and (2) TRPC5 protects against pathological cardiac hypertrophy.

Indexed as

CardiomegalyHeart RateMice, KnockoutTRPC Cation ChannelsAnimalsBlood PressureMaleMiceMice, Inbred C57BLMyocytes, CardiacTrpc5 protein, mouseTRPC Cation Channelscardiac hypertrophycardiac remodellingheart rateTRPC5

Identifiers

PMID38672459
PMCPMC11047837
OpenAlexW4393934636

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.